Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Receivables: 2009-2024

Historic Receivables for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $11.7 million.

  • Cumberland Pharmaceuticals' Receivables fell 7.78% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.9 million, marking a year-over-year decrease of 0.92%. This contributed to the annual value of $11.7 million for FY2024, which is 19.91% up from last year.
  • As of FY2024, Cumberland Pharmaceuticals' Receivables stood at $11.7 million, which was up 19.91% from $9.8 million recorded in FY2023.
  • Cumberland Pharmaceuticals' Receivables' 5-year high stood at $13.2 million during FY2022, with a 5-year trough of $6.9 million in FY2021.
  • For the 3-year period, Cumberland Pharmaceuticals' Receivables averaged around $11.5 million, with its median value being $11.7 million (2024).
  • Per our database at Business Quant, Cumberland Pharmaceuticals' Receivables tumbled by 44.44% in 2021 and then spiked by 91.41% in 2022.
  • Over the past 5 years, Cumberland Pharmaceuticals' Receivables (Yearly) stood at $12.4 million in 2020, then tumbled by 44.44% to $6.9 million in 2021, then skyrocketed by 91.41% to $13.2 million in 2022, then decreased by 25.87% to $9.8 million in 2023, then increased by 19.91% to $11.7 million in 2024.